This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dessy, C. Articles by Balligand, J.-L. Search for Related Content PubMed PubMed Citation Articles by Dessy, C. Articles by Balligand, J.-L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL NITRIC OXIDE Related Collections Cardiovascular Pharmacology Endothelium/vascular type/nitric oxide

(Circulation. 2005;112:1198-1205.)
© 2005 American Heart Association, Inc.

Vascular Medicine

Endothelial β₃-Adrenoreceptors Mediate Nitric Oxide–Dependent Vasorelaxation of Coronary Microvessels in Response to the Third-Generation β-Blocker Nebivolol

Chantal Dessy, PhD^*; Julie Saliez, BSc^*; Philippe Ghisdal, PhD; Géraldine Daneau, BSc; Irina I. Lobysheva, PhD; Françoise Frérart, BSc; Catharina Belge, MD; Karima Jnaoui, PhD; Philippe Noirhomme, MD; Olivier Feron, PhD; Jean-Luc Balligand, MD, PhD

From the Unit of Pharmacology and Therapeutics (C.D., J.S., P.G., G.D., I.I.L., F.F., C.B., K.J., O.F., J.-L.B.) and the Department of Cardiac Surgery (P.N.), Université Catholique de Louvain Medical School, Brussels, Belgium.

Correspondence to Jean-Luc Balligand, MD, PhD, Department of Medicine, Unit of Pharmacology and Therapeutics, FATH 5349, Université Catholique de Louvain, 53 Ave Mounier, B-1200 Brussels, Belgium. E-mail Balligand{at}mint.ucl.ac.be

Received December 30, 2004; revision received April 16, 2005; accepted May 9, 2005.

Background— The therapeutic effects of nonspecific β-blockers are limited by vasoconstriction, thus justifying the interest in molecules with ancillary vasodilating properties. Nebivolol is a selective β₁-adrenoreceptor antagonist that releases nitric oxide (NO) through incompletely characterized mechanisms. We identified endothelial β₃-adrenoreceptors in human coronary microarteries that mediate endothelium- and NO-dependent relaxation and hypothesized that nebivolol activates these β₃-adrenoreceptors.

Methods and Results— Nebivolol dose-dependently relaxed rodent coronary resistance microarteries studied by videomicroscopy (10 µmol/L, –86±6% of prostaglandin F2 contraction); this was sensitive to NO synthase (NOS) inhibition, unaffected by the β_1-2-blocker nadolol, and prevented by the β_1-2-3-blocker bupranolol (P<0.05; n=3 to 8). Importantly, nebivolol failed to relax microarteries from β₃-adrenoreceptor–deficient mice. Nebivolol (10 µmol/L) also relaxed human coronary microvessels (–71±5% of KCl contraction); this was dependent on a functional endothelium and NO synthase but insensitive to β_1-2-blockade (all P<0.05). In a mouse aortic ring assay of neoangiogenesis, nebivolol induced neocapillary tube formation in rings from wild-type but not β₃-adrenoreceptor– or endothelial NOS–deficient mice. In cultured endothelial cells, 10 µmol/L nebivolol increased NO release by 200% as measured by electron paramagnetic spin trapping, which was also reversed by NOS inhibition. In parallel, endothelial NOS was dephosphorylated on threonine⁴⁹⁵, and fura-2 calcium fluorescence increased by 91.8±23.7%; this effect was unaffected by β_1-2-blockade but abrogated by β_1-2-3-blockade (all P<0.05).

Conclusions— Nebivolol dilates human and rodent coronary resistance microarteries through an agonist effect on endothelial β₃-adrenoreceptors to release NO and promote neoangiogenesis. These properties may prove particularly beneficial for the treatment of ischemic and cardiac failure diseases through preservation of coronary reserve.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				D. Wenzel, R. Knies, M. Matthey, A. M. Klein, J. Welschoff, V. Stolle, P. Sasse, W. Roll, J. Breuer, and B. K. Fleischmann {beta}2-Adrenoceptor Antagonist ICI 118,551 Decreases Pulmonary Vascular Tone in Mice via a Gi/o Protein/Nitric Oxide-Coupled Pathway Hypertension, July 1, 2009; 54(1): 157 - 163. [Abstract] [Full Text] [PDF]

				J.-L. Balligand beta(3)-Adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade "Stop or Encore?". J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1539 - 1542. [Full Text] [PDF]

				M. Sato, D. S. Hutchinson, B. A. Evans, and R. J. Summers Mol. Pharmacol., November 1, 2008; 74(5): 1417 - 1428. [Abstract] [Full Text] [PDF]

				L. M. Prisant Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory {beta}1-Blocker J. Clin. Pharmacol., February 1, 2008; 48(2): 225 - 239. [Abstract] [Full Text] [PDF]

				R. Kou and T. Michel Epinephrine Regulation of the Endothelial Nitric-oxide Synthase: ROLES OF RAC1 AND beta3-ADRENERGIC RECEPTORS IN ENDOTHELIAL NO SIGNALING J. Biol. Chem., November 9, 2007; 282(45): 32719 - 32729. [Abstract] [Full Text] [PDF]

				L. L. Brunton A positive feedback loop contributes to the deleterious effects of angiotensin PNAS, October 11, 2005; 102(41): 14483 - 14484. [Full Text] [PDF]